BridgeBio posts Q3 net loss of $162M; acoramidis PDUFA set for Nov 29, 2024

BridgeBio Pharma, Inc.

2024-Q3 EPS reported -$1.46 revenue$216,020,000

Net loss per share of $0.86; revenue $2.7M vs $4.1M YoY; operating expenses $194.5M.
Cash, equivalents, and short-term restricted cash $405.7M; expects $500M milestone from acoramidis upon FDA approval.
FDA accepted acoramidis NDA; PDUFA date November 29, 2024; 42-month OLE data to be presented at AHA.
FDA granted Breakthrough Therapy Designation to oral infigratinib for achondroplasia.
Phase 3 FORTIFY trial for LGMD2I/R9 enrollment completed; interim analysis expected in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.